<i>In</i> <i>Situ</i> Programming of Nanovaccines for Lymph Node-Targeted Delivery and Cancer Immunotherapy

Jin, Liangjie; Yang, Dongmei; Song, Yonghong; Li, Dongdong; Xu, Weilin; Zhu, Yueqiang; Xu, Cong; Lu, Yang; Yang, Xianzhu

doi:10.1021/acsnano.2c06560

Cited by 20 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jin et al demonstrated an in situ cancer vaccine-based approach; in their study, they designed in situ vaccines by combining two synergetic approaches. First, ferrimagnetic nano cubes were encapsulated into an amphiphilic polymer, which generates the antigens by a magnetic field and destroys the primary tumor, and another polymeric nanoparticle coated with adjuvant R848 (resiquimod) delivers the formed antigens to the lymph node, activates the APCs and creates an antitumor immune response to distant tumors [ 139 ]. Li et al conducted another in situ based study.…”

Section: Cancer Immunotherapy Delivery Methodsmentioning

confidence: 99%

Recent Advances in Cancer Immunotherapy Delivery Modalities

et al. 2023

View full text Add to dashboard Cite

Immunotherapy is crucial in fighting cancer and achieving successful remission. Many novel strategies have recently developed, but there are still some obstacles to overcome before we can effectively attack the cancer cells and decimate the cancer environment by inducing a cascade of immune responses. To successfully demonstrate antitumor activity, immune cells must be delivered to cancer cells and exposed to the immune system. Such cutting-edge technology necessitates meticulously designed delivery methods with no loss or superior homing onto cancer environments, as well as high therapeutic efficacy and fewer adverse events. In this paper, we discuss recent advances in cancer immunotherapy delivery techniques, as well as their future prospects.

show abstract

Section: Cancer Immunotherapy Delivery Methodsmentioning

confidence: 99%

Recent Advances in Cancer Immunotherapy Delivery Modalities

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The ideal cancer vaccine to achieve efficient anti-tumor effects could have them targeted to immune organs to induce targeted activation in addition to conventional TAAs and immune adjuvants. Among the many immune organs, lymph nodes reside a large number of APCs and T cells, which are the front-runners for antitumor immunotherapy [ 48 , 49 ]. Sun et al [ 50 ] used B16-F10 tumor cell membranes to wrap aluminum phosphate nanoparticles and CpG to make nanoparticles APMC.…”

Section: Cell Membrane Modified Nanomaterialsmentioning

confidence: 99%

Nanomaterials: small particles show huge possibilities for cancer immunotherapy

et al. 2022

View full text Add to dashboard Cite

With the economy's globalization and the population's aging, cancer has become the leading cause of death in most countries. While imposing a considerable burden on society, the high morbidity and mortality rates have continuously prompted researchers to develop new oncology treatment options. Anti-tumor regimens have evolved from early single surgical treatment to combined (or not) chemoradiotherapy and then to the current stage of tumor immunotherapy. Tumor immunotherapy has undoubtedly pulled some patients back from the death. However, this strategy of activating or boosting the body's immune system hardly benefits most patients. It is limited by low bioavailability, low response rate and severe side effects. Thankfully, the rapid development of nanotechnology has broken through the bottleneck problem of anti-tumor immunotherapy. Multifunctional nanomaterials can not only kill tumors by combining anti-tumor drugs but also can be designed to enhance the body's immunity and thus achieve a multi-treatment effect. It is worth noting that the variety of nanomaterials, their modifiability, and the diversity of combinations allow them to shine in antitumor immunotherapy. In this paper, several nanobiotics commonly used in tumor immunotherapy at this stage are discussed, and they activate or enhance the body's immunity with their unique advantages. In conclusion, we reviewed recent advances in tumor immunotherapy based on nanomaterials, such as biological cell membrane modification, self-assembly, mesoporous, metal and hydrogels, to explore new directions and strategies for tumor immunotherapy.

show abstract

“…[36] In the last decades, nanotechnology has been used to enhance the effectiveness of the immune response to tumor vaccines by delivering tumor antigens to LNs using nanoparticles (NPs)-based carriers. [37][38][39] NPs with positive surface charges have the ability to adsorb tumor antigens and NPs can also codeliver tumor antigens and immunomodulators to further activate immune system. [40,41] Moreover, in previous studies, it was demonstrated that spherical NPs with a particle size of between 25-50 nm can rapidly reach DLNs through tissue barriers; NPs larger than 100 nm need to be transported to LNs via DCs, while NPs larger than 500 nm do not efficiently reach LNs owing to macrophages clearance.…”

Section: Introductionmentioning

confidence: 99%

In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant

Zhang

et al. 2023

Small

View full text Add to dashboard Cite

Tumor vaccine is a promising cancer treatment modality, however, the convenient antigens loading in vivo and efficient delivery of vaccines to lymph nodes (LNs) still remain a formidable challenge. Herein, an in situ nanovaccine strategy targeting LNs to induce powerful antitumor immune responses by converting the primary tumor into whole‐cell antigens and then delivering these antigens and nanoadjuvants simultaneously to LNs is proposed. The in situ nanovaccine is based on a hydrogel system, which loaded with doxorubicin (DOX) and nanoadjuvant CpG‐P‐ss‐M. The gel system exhibits ROS‐responsive release of DOX and CpG‐P‐ss‐M, generating abundant in situ storage of whole‐cell tumor antigens. CpG‐P‐ss‐M adsorbs tumor antigens through the positive surface charge and achieves charge reversal, forming small‐sized and negatively charged tumor vaccines in situ, which are then primed to LNs. Eventually, the tumor vaccine promotes antigens uptake by dendritic cells (DCs), maturation of DCs, and proliferation of T cells. Moreover, the vaccine combined with anti‐CTLA4 antibody and losartan inhibits tumor growth by 50%, significantly increasing the percentage of splenic cytotoxic T cells (CTLs), and generating tumor‐specific immune responses. Overall, the treatment effectively inhibits primary tumor growth and induces tumor‐specific immune response. This study provides a scalable strategy for in situ tumor vaccination.

show abstract

In Situ Programming of Nanovaccines for Lymph Node-Targeted Delivery and Cancer Immunotherapy

Cited by 20 publications

References 53 publications

Recent Advances in Cancer Immunotherapy Delivery Modalities

Recent Advances in Cancer Immunotherapy Delivery Modalities

Nanomaterials: small particles show huge possibilities for cancer immunotherapy

In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant

Contact Info

Product

Resources

About